{
    "clinical_study": {
        "@rank": "80587", 
        "arm_group": [
            {
                "arm_group_label": "Active First", 
                "arm_group_type": "Experimental", 
                "description": "Active resveratrol first, placebo second"
            }, 
            {
                "arm_group_label": "Placebo first", 
                "arm_group_type": "Experimental", 
                "description": "Placebo first, active resveratrol second"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study is designed to test the hypothesis that resveratrol supplementation will\n      improve the function of the endothelium in patients with type 2 diabetes mellitus.\n\n      The function of the endothelium will be tested with a non-invasive technique that uses\n      ultrasound to measure the amount of dilation that occurs in the brachial artery following\n      5-minute cuff occlusion. To help us understand potential mechanisms of benefit, we will also\n      collect blood, urine, and cell samples and test the effects of treatment on protein\n      expression, nitric oxide production, and function of mitochondria."
        }, 
        "brief_title": "Effects of Resveratrol on Endothelial Function in Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects\n\n          -  Age over 21 years old\n\n          -  Body mass index less than 38 kg/m2\n\n          -  Clinical stable type 2 diabetes mellitus\n\n        Exclusion Criteria:\n\n          -  Women who are lactating or pregnant\n\n          -  Treatment with an investigations product within 30 days of screening\n\n          -  Clinically evident major illness of other organ systems, including cancer, renal\n             failure, or other conditions in the opinion of the investigators that would make\n             clinical study inappropriate\n\n          -  Liver transaminase levels greater than 3 times the upper limit of normal\n\n          -  History of psychological illness or condition that would interfere with the subject's\n             ability to understand the requirements of the study\n\n          -  Vitamin supplements exceeding two times the recommended daily allowance\n\n          -  Resveratrol or other dietary supplements except for a daily multivitamin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881347", 
            "org_study_id": "H-32036", 
            "secondary_id": "5P01HL068758-10"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Active First", 
                    "Placebo first"
                ], 
                "description": "Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.", 
                "intervention_name": "Resveratrol", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Active First", 
                    "Placebo first"
                ], 
                "description": "Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Resveratrol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "endothelium", 
            "mitochondria", 
            "reactive oxygen species", 
            "vascular biology", 
            "arterial stiffness", 
            "nitric oxide"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "location": {
            "contact": {
                "email": "monica.holbrook@bmc.org", 
                "last_name": "Monika Holbrook, MS"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02118"
                }, 
                "name": "Boston University Medical Center"
            }, 
            "investigator": {
                "last_name": "Joseph A Vita, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Crossover Study of The Effects of Resveratrol on Endothelial Function in Subjects With Type 2 Diabetes Mellitus", 
        "other_outcome": [
            {
                "measure": "Change from Baseline in Serum glucose", 
                "safety_issue": "No", 
                "time_frame": "2 and 4 weeks"
            }, 
            {
                "measure": "Change from Baseline in Serum insulin", 
                "safety_issue": "No", 
                "time_frame": "2 and 4 weeks"
            }, 
            {
                "measure": "Change from Baseline in Mononuclear cell mitochondrial DNA damage", 
                "safety_issue": "No", 
                "time_frame": "4 weejs"
            }, 
            {
                "measure": "Change from Baseline in Mononuclear cell mitochondrial mass", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Change from Baseline in Mononuclear cell mitochondrial production of reactive oxygen species", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Change from Baseline in Endothelial cell gene expression", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Change from Baseline in Endothelial cell protein expression", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Boston University", 
            "last_name": "Joseph A Vita, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in Brachial artery flow mediated dilation", 
            "safety_issue": "No", 
            "time_frame": "2 hours, 2 weeks, and 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Fingertip peripheral arterial tonometry", 
                "safety_issue": "No", 
                "time_frame": "2 hours, 2 weeks, and 4 weeks"
            }, 
            {
                "measure": "Change from Baseline in Carotid femoral pulse wave velocity", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Change from Baseline in Reactive hyperemia", 
                "safety_issue": "No", 
                "time_frame": "2 hours, 2 weeks, 4 weeks"
            }
        ], 
        "source": "Boston University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Boston University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}